August 7, 2018
By: Andrew J. Miller
Budd Larner Follows Up Guaifenesin and Nasonex Trial Wins With a Trial Victory for Dr. Reddy’s Laboratories in Omeprazole OTC
Late last week, a Budd Larner trial team achieved a memorable court house victory for firm client Dr. Reddy’s Laboratories (“DRL”) against Dexcel Pharma (“Dexcel”).
The case arose when DRL filed an ANDA seeking regulatory approval to market a generic version of Dexcel’s over-the-counter (OTC) Omeprazole delayed release tablets. Dexcel filed a Hatch-Waxman suit against DRL, alleging that DRL’s ANDA product infringed its patents.
The U.S. District Court for the District of New Jersey commenced a bench trial in late July but cut short the trial after a crushing cross examination of a Dexcel expert witness by Budd Larner partner Constance Huttner
that made clear that Dexcel could not prevail. As a result, Dexcel conceded and consented to judgment in favor of Dr. Reddy’s.
The Budd Lamer trial team was headed by Huttner and Alan Pollack
along with associates Anandita Vyakarnam
, Caroline Sun
and Beth Finkelstein
. Budd Larner trial teams also secured trial wins last year for DRL in a case arising from DRL’s filing of an ANDA for a generic version of Guaifenesin and for Amneal in a case arising from Amneal’s filing of an ANDA for Nasonex.
For More Information, Contact:
Andrew J. Miller
Chair, Intellectual Property Group